TEAD1 and laryngeal carcinoma: Additional in vitro studies showed that WISP1 enhances drug resistance and inhibits ataxia-telangiectasia-mutated (ATM)-mediated DNA damage response in laryngeal cancer cells treated with cisplatin, by activating Yes-associated protein 1 (YAP1)/TEA domain transcription factor 1 (TEAD1) signaling, that contributes to GLUT1 upregulation [178].